Tag: survival

MONDAY, Oct. 15, 2018 — Among patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor, progression-free survival is significantly longer in those who receive treatment with brigatinib versus crizotinib, according to a study published online Sept. 25 in the New England Journal of Medicine. D.

The presence of the human high-risk papillomavirus (hrHPV) in the diagnosis of invasive cervical cancer is linked to a greatly improved prognosis compared to cases in which hrHPV cannot be identified in the tumour, according to researchers at Karolinska Institutet in Sweden, who have published their results in the scientific journal PLOS Medicine. The researchers

Cancer treatment continues to improve for many types of cancer, leading to increased life expectancy for many survivors. In fact, the number of cancer survivors is expected to reach nearly 18 million within the next decade in the U.S.1 For survivors of non-small cell lung cancer (NSCLC), the most common type of lung cancer, their

High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective than the other. For the first time, researchers have shown that more patients live longer if treated with the

Doctors use staging to help diagnose cancer, plan treatment, and explain a person’s outlook clearly. There are four stages, which people often write using Roman numerals. Stage 4 cancer will sometimes appear in writing as stage IV. Knowing what to expect from stage 4 bladder cancer can help people to make informed decisions about their

Further exploration into the endpoints of the NRG Oncology/RTOG 0424 trial resulted in the discovery that MGMT promoter methylation is an independent prognostic biomarker of high-risk, low-grade glioma treated with temozolomide and radiation. This is the first study of its kind to validate the prognostic significance of MGMT promoter methylation in this patient population and

(HealthDay)—Eating a nutritionally balanced high-quality diet may lower a cancer patient’s risk of dying by as much as 65 percent, new research suggests. The finding that total diet, rather than specific nutritional components, can affect a cancer patient’s prognosis “was particularly surprising to us,” said the study’s lead author, Ashish Deshmukh. Total diet, he explained,

A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity of post-treatment surveillance and detection of recurrence or overall survival (OS) in patients with stage I, II or III colorectal cancer (CRC). Published in the Journal of the American Medical Association, the study is

Researchers from the University of Jyväskylä in Finland have found that continued treatment of muscle wasting with a soluble growth factor receptor protein, produced at the University of Helsinki, improved survival in a pre-clinical cancer model without affecting the tumour size. This effect was not found when the mice were treated with the recombinant protein

Very small differences in the way a patient lies during radiotherapy treatment for lung or oesophageal cancer can have an impact on how likely they are to survive, according to research presented at the ESTRO 37 conference. These differences of only a few millimetres can mean that the radiation treatment designed to target patients’ tumours

Adolescents and young adults with acute leukemia have a survival advantage if they receive treatment at a pediatric cancer center versus an adult center, according to a new study. The study, published online today in Blood Advances, a journal of the American Society of Hematology, also suggests that treatment at a center affiliated with the

Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland. Researchers presented the three-year survival results of the randomised phase 2 POPLAR trial in second line, which is the longest follow-up reported to date with anti-programmed death ligand 1

Adding the monoclonal antibody drug trastuzumab—already used to treat certain breast cancers—to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value.